BayPAP is a program designed to assist Malaysian patient who have been diagnosed and prescribed with Nexavar or Stivarga by their doctors. BayPAP is part of Bayer Healthcare’s initiative to provide drug assistance to Malaysian patients in helping them to continue their treatments for as long as it is medically required.

1. 1. Malaysian citizen / Malaysian Permanent Resident
2. 2. Fixed annual income not exceeding RM 150, 000
3. 3. Prescribed Nexavar or Stivarga for approved indications by the doctor
4. 4. Drug purchased in Malaysia

We are committed to process your application within 3 business days upon receiving all necessary forms and supporting documents via the portal.

We apologise that we are unable to provide further support to your treatment in this instance. Should there be changes in your income/insurance status, please let us know and we will review your application again.

Bayer has appointed Zuellig Pharma as the partner to administer the program on its behalf. This partnership is to ensure independence and transparent execution of the BayPAP.

Zuellig Pharma’s Role:

1. 1. Administrator of the patient and doctor’s portals
2. 2. Evaluate the patient’s applications and notify the patient and the prescribing doctor on the application outcome via the portal. Retain and archive the application forms for record purposes.
3. 3. Validate the patient’s sales receipt or invoice as a prerequisite for the supply of free program good.
4. 4. Deliver the free program good to designated dispensing point as prearranged with the treating physician.
5. 5. Track the redemption letter and acknowledgement of the free program good via the portal.
6. 6. Report adverse events (AE) and/or product technical complaints (PTC) that are identifies during the conduct of this program to Bayer. These causes may be subsequently submitted to the local Heath Authority by Bayer if applicable.

Zuellig Pharma will only share patient’s personal confidential information as required for purposes to determine the eligibility for BayPAP enrolment and/or facilitate the administration of BayPAP. Only program performance and aggregated data will be shared as part of the program service.

1. 1. Assess the patient’s eligibility for BayPAP.
2. 2. Provide the eligible patient with the BayPAP enrolment information Patient Kit.
3. 3. Report any AE to Bayer via the portal.

Support is available via email mybaypap@zuelligpharma.com or calling +603-2027 4621.